Enfrentamiento del prurito secundario a enfermedades hepáticas

Los receptores del farnesoid X también reducen y regulan la síntesis de ácidos biliares a través de varios mecanismos, aun desconocidos. (³²⁾

Discusión

El prurito es una importante queja en los pacientes con colestasis y puede tener serios efectos en la calidad de vida. A pesar de la disponibilidad de muchas opciones terapéuticas, no existe ningún protocolo normal para el tratamiento del prurito en los pacientes con colestasis. Más allá se necesitan ensayos clínicos para establecer un sistema de la clasificación conveniente y un protocolo terapéutico eficaz para mejorar el manejo del prurito en los pacientes con colestasis.

Los estudios apuntan al control de la población de nociceptores lo que podría dar más luz a la fisiopatología del prurito y como el dolor afecta la respuesta pruriginosa.

Referencias bibliográficas

1. Zein CO, Lindor KD. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 2010; 12: 13–22.
2. Rishe E, Azarm A, Bergasa NV. Itch in primary biliary cirrhosis: a patients’ perspective. Acta Derm. Venereol. 2008; 88: 34–7.
3. Bergasa NV. The itch of liver disease. Semin. Cutan. Med. Surg. 2011; 30: 93–8.
4. Pathak B, Sheibani L, Lee RH. Cholestasis of pregnancy. Obstet. Gynecol. Clin. North Am. 2010; 37: 269–82.
5. Patel KN, Dong X. Itch: cells, molecules, and circuits. ACS Chem. Neurosci. 2011; 2: 17–25.
6. Imamachi N, Park GH, Lee H. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc. Natl. Acad. Sci. USA 2009; 106: 11 330–5.
7. Kremer AE, Martens JJ, Kulik W. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010; 139: 1008–18. 1018 e1001.
8. Oude Elferink RP, Kremer AE, Martens JJ, Beuers UH. The molecular mechanism of cholestatic pruritus. Dig. Dis. 2011; 29: 66–71.
9. Fiorucci S, Clerici C, Antonelli E. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 2005; 313: 604–12.
10. Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, Bigliardi-Qi M. Opioids and the skin—where do we stand? Exp. Dermatol. 2009; 18: 424–30.
11. Greaves MW. Pathogenesis and treatment of pruritus. Curr. Allergy Asthma Rep. 2010; 10: 236–42.
12. Yamamoto A, Sugimoto Y. Involvement of peripheral mu opioid receptors in scratching behavior in mice. Eur. J. Pharmacol. 2010; 649: 336–41.
13. Imam, M. H., Gossard, A. A., Sinakos, E. and Lindor, K. D. Pathogenesis and management of pruritus in cholestatic liver disease. Journal of Gastroenterology and Hepatology,2012; 27: 1150–8
14. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology 2004; 40: 467–74.
15. Shi J, Li Z, Zeng X, Lin Y, Xie WF. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol. Res. 2009; 39: 865–73.
16. Yosipovitch G, Zucker I, Boner G, Gafter U, Shapira Y, David M. A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm. Venereol. 2001; 81: 108–11.
17. Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic itch using the “Eppendorf” The 5-D itch scale: a new measure of pruritus. Br. J. Dermatol. 2010; 162: 587–93.
18. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br. J. Dermatol. 2010; 162: 587–93.
19. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009; 50: 291–308.
20. Feramisco JD, Berger TG, Steinhoff M. Innovative management of pruritus. Dermatol. Clin. 2010; 28: 467–78.
21. Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 2003; 38 (Suppl. 1): S24–37.
22. Pellicciari R, Fiorucci S, Camaioni E. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 2002; 45: 3569–72.
23. Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009; 49: 297–305.
24. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006; 26: 943–8.
25. Yue J, Peng R, Chen J, Liu Y, Dong G. Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats. Pharmacol. Res. 2009; 59: 112–19.
26. Phan NQ, Bernhard JD, Luger TA, Stander S. Antipruritic treatment with systemic mu-opioid receptor antagonists: a review. J. Am. Acad. Dermatol. 2010; 63: 680–8.
27. Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin. Liver Dis. 2008; 12: 385–406. x.
28. Zellos A, Roy A, Schwarz KB. Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children. J. Pediatr. Gastroenterol. Nutr. 2010; 51: 787–9.
29. Eschler DC, Klein PA. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J. Drugs Dermatol. 2010; 9: 992–7.
30. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45: 666–74.
31. Alallam A, Barth D, Heathcote EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can. J. Gastroenterol. 2008; 22: 505–7.
32. Inagaki T, Choi M, Moschetta A. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005; 2: 217–25.
33. Mason A, Lv LK, Hirschfield G. Farnesoid -X receptor agonists: a new class of drugs for the treatment of pbc. J. Hepatol. 2010; 52 (Suppl): S1–S2.